Cargando…
Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?
The current understanding of the molecular biology of breast cancer presents an extremely complex portrait of the disease. Based on this knowledge, considerable efforts are being made to identify biomarkers that will predict the response to a specific treatment while minimizing the risk of unnecessa...
Autores principales: | Pérez-García, José, Cortés, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496127/ https://www.ncbi.nlm.nih.gov/pubmed/22297134 http://dx.doi.org/10.1186/bcr3093 |
Ejemplares similares
-
Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019) -
The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020) -
Do we need a scientific journal?
por: Fernandes, Francisco Cortes
Publicado: (2021) -
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer
por: Mitin, Natalia, et al.
Publicado: (2022) -
Why do we Need Quality Articles, What are we Going to do With?
por: Mueen Ahmed, KK
Publicado: (2011)